Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWTX Edgewise Therapeutics	$14.78 +2.3%	$16.96	$10.60 ▼ $38.12	$1.55B	0.36	1.17 million shs	1.28 million shs
INDV Indivior	$11.34 +2.4%	$10.11	$7.33 ▼ $18.59	$1.56B	0.98	1.01 million shs	1.09 million shs
JANX Janux Therapeutics	$24.28 +4.3%	$28.66	$22.48 ▼ $71.71	$1.44B	3.24	868,653 shs	931,458 shs
KMDA Kamada	$6.94 +1.2%	$6.60	$4.74 ▼ $9.16	$394.31M	0.94	89,238 shs	37,134 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWTX Edgewise Therapeutics	0.00%	+1.37%	+10.25%	-41.79%	-16.40%
INDV Indivior	0.00%	+2.25%	+25.86%	+15.36%	-35.27%
JANX Janux Therapeutics	0.00%	-5.01%	-18.22%	-33.24%	-48.86%
KMDA Kamada	0.00%	+0.87%	+6.77%	-10.80%	+24.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EWTX Edgewise Therapeutics	2.938 of 5 stars	4.4	1.0	2.8	3.3	0.0
INDV Indivior	3.3391 of 5 stars	3.6	3.0	2.6	1.7	1.9
JANX Janux Therapeutics	2.3343 of 5 stars	3.5	0.0	4.1	3.3	0.0
KMDA Kamada	3.9889 of 5 stars	3.4	3.0	2.5	1.7	3.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$40.22	172.14% Upside
INDV Indivior	3.25	Buy	$15.00	32.28% Upside
JANX Janux Therapeutics	3.09	Buy	$95.25	292.30% Upside
KMDA Kamada	2.75	Moderate Buy	$14.67	111.34% Upside

Current Analyst Ratings Breakdown

Latest KMDA, INDV, EWTX, and JANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/8/2025	KMDA Kamada	Sidoti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/30/2025	EWTX Edgewise Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00
4/21/2025	EWTX Edgewise Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$43.00 ➝ $43.00
4/3/2025	EWTX Edgewise Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $52.00
4/2/2025	EWTX Edgewise Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $51.00
4/2/2025	EWTX Edgewise Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$50.00 ➝ $14.00
3/21/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
3/7/2025	EWTX Edgewise Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$50.00
3/6/2025	INDV Indivior	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $13.00
3/6/2025	KMDA Kamada	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.53 per share	N/A
INDV Indivior	$1.17B	1.34	$2.30 per share	4.94	N/A	∞
JANX Janux Therapeutics	$9.34M	153.90	N/A	N/A	$7.46 per share	3.25
KMDA Kamada	$160.95M	2.48	$0.39 per share	17.90	$4.25 per share	1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EWTX Edgewise Therapeutics	-$100.16M	-$1.55	N/A	N/A	N/A	N/A	-26.83%	-25.67%	N/A
INDV Indivior	$2M	-$0.31	N/A	6.63	N/A	-3.96%	-241.73%	15.09%	7/24/2025 (Estimated)
JANX Janux Therapeutics	-$58.29M	-$1.36	N/A	N/A	N/A	-463.91%	-10.47%	-9.86%	N/A
KMDA Kamada	$8.28M	$0.29	24.79	21.69	0.97	9.92%	6.30%	4.49%	N/A

Latest KMDA, INDV, EWTX, and JANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million
3/3/2025	Q4 2024	EWTX Edgewise Therapeutics	-$0.39	-$0.42	-$0.03	-$0.42	N/A	N/A
2/27/2025	Q4 2024	JANX Janux Therapeutics	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
2/20/2025	Q4 2024	INDV Indivior	$0.32	$0.32	N/A	$0.07	$262.35 million	$298.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A

Latest KMDA, INDV, EWTX, and JANX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/5/2025	KMDA Kamada	--	$0.20		3/17/2025	3/17/2025	4/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EWTX Edgewise Therapeutics	N/A	26.35	26.35
INDV Indivior	N/A	0.83	0.65
JANX Janux Therapeutics	N/A	38.80	38.80
KMDA Kamada	N/A	4.84	2.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EWTX Edgewise Therapeutics	N/A
INDV Indivior	60.33%
JANX Janux Therapeutics	75.39%
KMDA Kamada	20.38%

Insider Ownership

Company	Insider Ownership
EWTX Edgewise Therapeutics	23.20%
INDV Indivior	N/A
JANX Janux Therapeutics	8.10%
KMDA Kamada	36.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EWTX Edgewise Therapeutics	60	105.20 million	71.86 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
JANX Janux Therapeutics	30	59.18 million	37.05 million	Optionable
KMDA Kamada	360	57.48 million	36.73 million	Optionable

KMDA, INDV, EWTX, and JANX Headlines

Recent News About These Companies

Kamada's (KMDA) Buy Rating Reaffirmed at Benchmark

May 17 at 3:41 AM | americanbankingnews.com

Is Kamada (KMDA) Stock Undervalued Right Now?

May 16 at 11:45 AM | msn.com

Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade

May 16 at 11:45 AM | msn.com

Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion

May 15 at 8:58 PM | finance.yahoo.com

Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics

May 15 at 8:58 PM | msn.com

Kamada Ltd. (NASDAQ:KMDA) Q1 2025 Earnings Call Transcript

May 15 at 8:58 PM | msn.com

Kamada Ltd. (KMDA) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Kamada (KMDA) Q1 Earnings Match Estimates

May 14, 2025 | zacks.com

Kamada Reports Strong Q1 2025 Financial Results and Expands Plasma Operations

May 14, 2025 | tipranks.com

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

May 14, 2025 | globenewswire.com

Earnings Preview For Kamada

May 14, 2025 | benzinga.com

Kamada Q1 2025 Earnings Preview

May 14, 2025 | msn.com

Kamada (KMDA) Projected to Post Quarterly Earnings on Wednesday

May 13, 2025 | americanbankingnews.com

Kamada (NASDAQ:KMDA) Upgraded at Sidoti

May 12, 2025 | marketbeat.com

Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

May 9, 2025 | zacks.com

Kamada (KMDA) to Release Earnings on Wednesday

May 9, 2025 | marketbeat.com

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

May 5, 2025 | finance.yahoo.com

Crystal Palace news: Fan views on FA Cup, Glasner and Kamada

May 1, 2025 | msn.com

Kamada eager to make FA Cup history with Palace after super semi performance

April 28, 2025 | tribalfootball.com

Kamada on Wembley magic and chasing history

April 27, 2025 | cpfc.co.uk

EQS-News: Kamada Expects Third Plasma Collection Site To Support Its Hyper-Immune Plasma Needs And Add Up To $10M In Annual Revenue At Full Capacity

April 22, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, INDV, EWTX, and JANX Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

$14.78 +0.33 (+2.28%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$14.77 -0.01 (-0.04%)

As of 05/16/2025 06:16 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Indivior NASDAQ:INDV

$11.34 +0.27 (+2.44%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$11.32 -0.02 (-0.18%)

As of 05/16/2025 04:07 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Janux Therapeutics NASDAQ:JANX

$24.28 +1.01 (+4.34%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$24.40 +0.13 (+0.51%)

As of 05/16/2025 06:59 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Kamada NASDAQ:KMDA

$6.94 +0.08 (+1.17%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$6.90 -0.05 (-0.65%)

As of 05/16/2025 06:54 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time